Your Asthma Action Plan


Coming up with an asthma action plan with your child's doctor is a great way to help keep your child's asthma under control.

For your next scheduled appointment, print out the asthma action plan and take it with you to your child's visit. After developing the plan with your child's doctor, you'll have a better understanding of

  • When to use a controller medicine, when to add a quick-relief medicine, and when to get immediate help from a doctor
  • The signs and symptoms during each stage of your child's action plan
  • Common triggers to avoid

Your asthma action plan also helps you and other caregivers understand when and how to use your child's controller and quick-relief asthma medications. A copy of your plan should be given to all close family members, as well as teachers, day care providers, and babysitters. Review the plan regularly with your child's doctor, and be sure to get your child involved as well.

Show each caregiver how your child's asthma action plan works and also how to look for both quiet and loud symptoms. Make sure to also share the plan with your child. Although your child may not understand all the details, he or she should know when and how to use it. Your child's asthma action plan is a key factor in helping you, your child, and other caregivers know when to take action.

"I have my child's asthma action plan ready when I have to visit the doctor, and it helps me and the office track my child's progress."
-Norma H. Mom of child with asthma
Results may vary.


Some files on this page require Adobe® Reader® to be installed. If you do not have Adobe Reader on your computer, you can download it here

Did You Know?


PULMICORT RESPULES is a maintenance medicine used to control and prevent asthma symptoms in children ages
12 months to 8 years

1171404-3175607 Last updated 9/15


Important Safety Information

PULMICORT RESPULES is not a bronchodilator and should NOT be used to treat an acute asthma attack. If your child is switching to PULMICORT RESPULES from an oral corticosteroid, follow the doctor's instructions to avoid serious health risks when your child stops using oral corticosteroids.

Only use PULMICORT RESPULES with a jet nebulizer machine that is connected to an air compressor. Do not use an ultrasonic nebulizer.

Thrush infection of the mouth and throat may occur with PULMICORT RESPULES.

Avoid exposure of your child to infections such as chicken pox and measles. Tell your doctor immediately if your child is exposed.

Inhaled corticosteroids may cause a reduction in growth rate. The long-term effect on final adult height is unknown.

PULMICORT RESPULES should not be used if your child is allergic to budesonide or any of the ingredients.

Be sure to tell the healthcare provider about all your child's health conditions and all medicines he or she may be taking.

As with other inhaled asthma medications, bronchospasm, with an immediate increase in wheezing, may occur after dosing. If bronchospasm occurs following dosing with PULMICORT RESPULES, it should be treated immediately with a fast-acting inhaled bronchodilator. Treatment with PULMICORT RESPULES should be stopped and your physician consulted.

The most common side effects include respiratory infection, runny nose, coughing, ear infection, viral infection, thrush in the mouth and throat, inflammation of the stomach including vomiting, diarrhea, abdominal pain and loss of appetite, nose bleed, pink eye, and rash.

Approved Use

PULMICORT RESPULES® (budesonide inhalation suspension) is a maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to 8 years.

Please click here for full Prescribing Information for PULMICORT RESPULES.

You may report side effects related to AstraZeneca products by clicking here.

This product information is intended for US consumers only.

PULMICORT RESPULES is a registered trademark of the AstraZeneca group of companies.

PARI JET PLUS Nebulizer and PARI MASTER Compressor are registered trademarks of PARI Respiratory Equipment, Inc.

©2019 AstraZeneca. All rights reserved. 1171404; US-16540; US-26850 Last Updated 2/19